The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Sterile Intravenous (IV) Solution Market Research Report 2025
Synopsis
Sterile Intravenous (IV), also known as sterile Intravenous therapy is a therapy that delivers liquid which is in medical use into a vein.
The global Sterile Intravenous (IV) Solution market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Sterile Intravenous (IV) Solution is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Sterile Intravenous (IV) Solution is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Sterile Intravenous (IV) Solution in Medications is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Sterile Intravenous (IV) Solution include B. Braun Medical Inc., Technoflex, Baxter International, ICU Medical, Inc, Mckesson, Amsino, Wallcur, Hebei Guangren Pharmaceutical Technology and Jiangsu Hengfengqiang Biotechnology, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Sterile Intravenous (IV) Solution, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Sterile Intravenous (IV) Solution.
Report Scope
The Sterile Intravenous (IV) Solution market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Sterile Intravenous (IV) Solution market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Sterile Intravenous (IV) Solution companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
B. Braun Medical Inc.
Technoflex
Baxter International
ICU Medical, Inc
Mckesson
Amsino
Wallcur
Hebei Guangren Pharmaceutical Technology
Jiangsu Hengfengqiang Biotechnology
Hospira
Jiangsu Hengfengqiang Biotechnology
Hospira
Xi'an Libang Alliance Enterprise Management
Livzon Group
Segment by Type
Crystalloids
Colloids
Others
Segment by Application
Medications
NutritionNutrition
Blood-based Products
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Sterile Intravenous (IV) Solution companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Sterile Intravenous (IV), also known as sterile Intravenous therapy is a therapy that delivers liquid which is in medical use into a vein.
The global Sterile Intravenous (IV) Solution market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Sterile Intravenous (IV) Solution is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Sterile Intravenous (IV) Solution is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Sterile Intravenous (IV) Solution in Medications is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Sterile Intravenous (IV) Solution include B. Braun Medical Inc., Technoflex, Baxter International, ICU Medical, Inc, Mckesson, Amsino, Wallcur, Hebei Guangren Pharmaceutical Technology and Jiangsu Hengfengqiang Biotechnology, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Sterile Intravenous (IV) Solution, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Sterile Intravenous (IV) Solution.
Report Scope
The Sterile Intravenous (IV) Solution market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Sterile Intravenous (IV) Solution market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Sterile Intravenous (IV) Solution companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
B. Braun Medical Inc.
Technoflex
Baxter International
ICU Medical, Inc
Mckesson
Amsino
Wallcur
Hebei Guangren Pharmaceutical Technology
Jiangsu Hengfengqiang Biotechnology
Hospira
Jiangsu Hengfengqiang Biotechnology
Hospira
Xi'an Libang Alliance Enterprise Management
Livzon Group
Segment by Type
Crystalloids
Colloids
Others
Segment by Application
Medications
NutritionNutrition
Blood-based Products
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Sterile Intravenous (IV) Solution companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Sterile Intravenous (IV) Solution Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Crystalloids
1.2.3 Colloids
1.2.4 Others
1.3 Market by Application
1.3.1 Global Sterile Intravenous (IV) Solution Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Medications
1.3.3 NutritionNutrition
1.3.4 Blood-based Products
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Sterile Intravenous (IV) Solution Market Perspective (2019-2030)
2.2 Sterile Intravenous (IV) Solution Growth Trends by Region
2.2.1 Global Sterile Intravenous (IV) Solution Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Sterile Intravenous (IV) Solution Historic Market Size by Region (2019-2024)
2.2.3 Sterile Intravenous (IV) Solution Forecasted Market Size by Region (2025-2030)
2.3 Sterile Intravenous (IV) Solution Market Dynamics
2.3.1 Sterile Intravenous (IV) Solution Industry Trends
2.3.2 Sterile Intravenous (IV) Solution Market Drivers
2.3.3 Sterile Intravenous (IV) Solution Market Challenges
2.3.4 Sterile Intravenous (IV) Solution Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Sterile Intravenous (IV) Solution Players by Revenue
3.1.1 Global Top Sterile Intravenous (IV) Solution Players by Revenue (2019-2024)
3.1.2 Global Sterile Intravenous (IV) Solution Revenue Market Share by Players (2019-2024)
3.2 Global Sterile Intravenous (IV) Solution Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Sterile Intravenous (IV) Solution Revenue
3.4 Global Sterile Intravenous (IV) Solution Market Concentration Ratio
3.4.1 Global Sterile Intravenous (IV) Solution Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Sterile Intravenous (IV) Solution Revenue in 2023
3.5 Sterile Intravenous (IV) Solution Key Players Head office and Area Served
3.6 Key Players Sterile Intravenous (IV) Solution Product Solution and Service
3.7 Date of Enter into Sterile Intravenous (IV) Solution Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Sterile Intravenous (IV) Solution Breakdown Data by Type
4.1 Global Sterile Intravenous (IV) Solution Historic Market Size by Type (2019-2024)
4.2 Global Sterile Intravenous (IV) Solution Forecasted Market Size by Type (2025-2030)
5 Sterile Intravenous (IV) Solution Breakdown Data by Application
5.1 Global Sterile Intravenous (IV) Solution Historic Market Size by Application (2019-2024)
5.2 Global Sterile Intravenous (IV) Solution Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Sterile Intravenous (IV) Solution Market Size (2019-2030)
6.2 North America Sterile Intravenous (IV) Solution Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Sterile Intravenous (IV) Solution Market Size by Country (2019-2024)
6.4 North America Sterile Intravenous (IV) Solution Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Sterile Intravenous (IV) Solution Market Size (2019-2030)
7.2 Europe Sterile Intravenous (IV) Solution Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Sterile Intravenous (IV) Solution Market Size by Country (2019-2024)
7.4 Europe Sterile Intravenous (IV) Solution Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Sterile Intravenous (IV) Solution Market Size (2019-2030)
8.2 Asia-Pacific Sterile Intravenous (IV) Solution Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Sterile Intravenous (IV) Solution Market Size by Region (2019-2024)
8.4 Asia-Pacific Sterile Intravenous (IV) Solution Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Sterile Intravenous (IV) Solution Market Size (2019-2030)
9.2 Latin America Sterile Intravenous (IV) Solution Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Sterile Intravenous (IV) Solution Market Size by Country (2019-2024)
9.4 Latin America Sterile Intravenous (IV) Solution Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Sterile Intravenous (IV) Solution Market Size (2019-2030)
10.2 Middle East & Africa Sterile Intravenous (IV) Solution Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Sterile Intravenous (IV) Solution Market Size by Country (2019-2024)
10.4 Middle East & Africa Sterile Intravenous (IV) Solution Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 B. Braun Medical Inc.
11.1.1 B. Braun Medical Inc. Company Detail
11.1.2 B. Braun Medical Inc. Business Overview
11.1.3 B. Braun Medical Inc. Sterile Intravenous (IV) Solution Introduction
11.1.4 B. Braun Medical Inc. Revenue in Sterile Intravenous (IV) Solution Business (2019-2024)
11.1.5 B. Braun Medical Inc. Recent Development
11.2 Technoflex
11.2.1 Technoflex Company Detail
11.2.2 Technoflex Business Overview
11.2.3 Technoflex Sterile Intravenous (IV) Solution Introduction
11.2.4 Technoflex Revenue in Sterile Intravenous (IV) Solution Business (2019-2024)
11.2.5 Technoflex Recent Development
11.3 Baxter International
11.3.1 Baxter International Company Detail
11.3.2 Baxter International Business Overview
11.3.3 Baxter International Sterile Intravenous (IV) Solution Introduction
11.3.4 Baxter International Revenue in Sterile Intravenous (IV) Solution Business (2019-2024)
11.3.5 Baxter International Recent Development
11.4 ICU Medical, Inc
11.4.1 ICU Medical, Inc Company Detail
11.4.2 ICU Medical, Inc Business Overview
11.4.3 ICU Medical, Inc Sterile Intravenous (IV) Solution Introduction
11.4.4 ICU Medical, Inc Revenue in Sterile Intravenous (IV) Solution Business (2019-2024)
11.4.5 ICU Medical, Inc Recent Development
11.5 Mckesson
11.5.1 Mckesson Company Detail
11.5.2 Mckesson Business Overview
11.5.3 Mckesson Sterile Intravenous (IV) Solution Introduction
11.5.4 Mckesson Revenue in Sterile Intravenous (IV) Solution Business (2019-2024)
11.5.5 Mckesson Recent Development
11.6 Amsino
11.6.1 Amsino Company Detail
11.6.2 Amsino Business Overview
11.6.3 Amsino Sterile Intravenous (IV) Solution Introduction
11.6.4 Amsino Revenue in Sterile Intravenous (IV) Solution Business (2019-2024)
11.6.5 Amsino Recent Development
11.7 Wallcur
11.7.1 Wallcur Company Detail
11.7.2 Wallcur Business Overview
11.7.3 Wallcur Sterile Intravenous (IV) Solution Introduction
11.7.4 Wallcur Revenue in Sterile Intravenous (IV) Solution Business (2019-2024)
11.7.5 Wallcur Recent Development
11.8 Hebei Guangren Pharmaceutical Technology
11.8.1 Hebei Guangren Pharmaceutical Technology Company Detail
11.8.2 Hebei Guangren Pharmaceutical Technology Business Overview
11.8.3 Hebei Guangren Pharmaceutical Technology Sterile Intravenous (IV) Solution Introduction
11.8.4 Hebei Guangren Pharmaceutical Technology Revenue in Sterile Intravenous (IV) Solution Business (2019-2024)
11.8.5 Hebei Guangren Pharmaceutical Technology Recent Development
11.9 Jiangsu Hengfengqiang Biotechnology
11.9.1 Jiangsu Hengfengqiang Biotechnology Company Detail
11.9.2 Jiangsu Hengfengqiang Biotechnology Business Overview
11.9.3 Jiangsu Hengfengqiang Biotechnology Sterile Intravenous (IV) Solution Introduction
11.9.4 Jiangsu Hengfengqiang Biotechnology Revenue in Sterile Intravenous (IV) Solution Business (2019-2024)
11.9.5 Jiangsu Hengfengqiang Biotechnology Recent Development
11.10 Hospira
11.10.1 Hospira Company Detail
11.10.2 Hospira Business Overview
11.10.3 Hospira Sterile Intravenous (IV) Solution Introduction
11.10.4 Hospira Revenue in Sterile Intravenous (IV) Solution Business (2019-2024)
11.10.5 Hospira Recent Development
11.11 Jiangsu Hengfengqiang Biotechnology
11.11.1 Jiangsu Hengfengqiang Biotechnology Company Detail
11.11.2 Jiangsu Hengfengqiang Biotechnology Business Overview
11.11.3 Jiangsu Hengfengqiang Biotechnology Sterile Intravenous (IV) Solution Introduction
11.11.4 Jiangsu Hengfengqiang Biotechnology Revenue in Sterile Intravenous (IV) Solution Business (2019-2024)
11.11.5 Jiangsu Hengfengqiang Biotechnology Recent Development
11.12 Hospira
11.12.1 Hospira Company Detail
11.12.2 Hospira Business Overview
11.12.3 Hospira Sterile Intravenous (IV) Solution Introduction
11.12.4 Hospira Revenue in Sterile Intravenous (IV) Solution Business (2019-2024)
11.12.5 Hospira Recent Development
11.13 Xi'an Libang Alliance Enterprise Management
11.13.1 Xi'an Libang Alliance Enterprise Management Company Detail
11.13.2 Xi'an Libang Alliance Enterprise Management Business Overview
11.13.3 Xi'an Libang Alliance Enterprise Management Sterile Intravenous (IV) Solution Introduction
11.13.4 Xi'an Libang Alliance Enterprise Management Revenue in Sterile Intravenous (IV) Solution Business (2019-2024)
11.13.5 Xi'an Libang Alliance Enterprise Management Recent Development
11.14 Livzon Group
11.14.1 Livzon Group Company Detail
11.14.2 Livzon Group Business Overview
11.14.3 Livzon Group Sterile Intravenous (IV) Solution Introduction
11.14.4 Livzon Group Revenue in Sterile Intravenous (IV) Solution Business (2019-2024)
11.14.5 Livzon Group Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
